80 FR 31601 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 80, Issue 106 (June 3, 2015)

The Food and Drug Administration (FDA) is announcing that a collection of information entitled, ``Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

[Federal Register Volume 80, Number 106 (Wednesday, June 3, 2015)]
[Notices]
[Pages 31601-31602]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-13473]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0168]


Agency Information Collection Activities; Announcement of Office 
of Management and Budget Approval; Disclosure Regarding Additional 
Risks in Direct-to-Consumer Prescription Drug Television Advertisements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
collection of information entitled, ``Disclosure Regarding Additional 
Risks in Direct-to-Consumer Prescription Drug Television 
Advertisements'' has been approved by the Office of Management and 
Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, [email protected].

SUPPLEMENTARY INFORMATION: On January 15, 2015, the Agency submitted a 
proposed collection of information entitled, ``Disclosure Regarding 
Additional Risks in Direct-to-Consumer Prescription Drug Television 
Advertisements'' to OMB for review and clearance under 44 U.S.C. 3507. 
An Agency may not conduct or sponsor, and a person is not required to 
respond to, a collection of information unless it displays a currently 
valid OMB control

[[Page 31602]]

number. OMB has now approved the information collection and has 
assigned OMB control number 0910-0785. The approval expires on May 31, 
2018. A copy of the supporting statement for this information 
collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.

    Dated: May 29, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-13473 Filed 6-2-15; 8:45 am]
BILLING CODE 4164-01-P